Мексиприм® tablets

General characteristics. Structure:

Acting substance — ethylmethylhydroxypyridine of succinate of 125 m of. Excipients (kernel): Kaolin, sodium carboxymethylstarch, cellulose microcrystallic, povidone, talc, calcium stearate. Excipients (cover): Gipromelloza, macrogoal, titanium dioxide, talc.

Pharmacological properties:

Pharmacodynamics. Мексиприм® treats heteroaromatic antioxidants. Has a wide range of pharmacological activity: increases resistance of an organism to a stress, shows the anxiolytic action which is not followed by miorelaksantny effect; has nootropic properties, warns and reduces the disturbances of training and memory arising during the aging and influence of various pathogenic factors; has anticonvulsant effect; shows antioxidant and anti-hypoxemic properties; increases concentration of attention and working capacity; weakens toxic effect of alcohol. Drug improves metabolism of tissues of brain and their blood supply, improves microcirculation and rheological properties of blood, reduces aggregation of thrombocytes. Stabilizes membrane structures of blood cells (erythrocytes and thrombocytes).

Possesses hypolipidemic action, reduces the content of the general cholesterol and lipoproteids of low density. The mechanism of action Meksiprima® is caused by its antioxidant and membranoprotektorny action. It inhibits peroxide oxidation of lipids, the superoxydock increases activity

sidaza, the ratio raises a lipid protein, reduces viscosity of a membrane, increases its flowability. Modulates activity of membrane-bound enzymes (kaltsiynezavisimy phosphodiesterase, adenylatecyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GAMK, atsetilkholinovy) that increases their ability of linkng with ligands, promotes preservation of structurally functional organization of biomembranes, transport of neurotransmitters and improvement of synoptic transfer. Мексиприм® increases contents in a dopamine brain. Causes strengthening of compensatory activation of aerobic glycolysis and decrease in extent of oppression of oxidizing processes in a tricarbonic acid cycle in the conditions of a hypoxia with increase in content of ATP and creatine phosphate, activation of the power synthesizing functions of mitochondrions, stabilization of cellular membranes.

Pharmacokinetics. Мексиприм®   0,08–0,1 hours are quickly soaked up from digestive tract with the semi-absorption period. Time of achievement of the maximum concentration in a blood plasma makes 0,46–0,5 hours. The size of the maximum concentration Meksiprima® in a blood plasma is in   range from 50 to 100 ng/ml. The elimination half-life of Meksiprima® and average time of deduction of drug in an organism make respectively 4,7-5,0 hours and 4,9–5,2 hours. Мексиприм®в a human body it is intensively metabolized with formation of its glyukuronokonjyugirovanny product. On average in 12 hours with urine 0,3% of not changed drug and 50% in the form of a glyukuronokonjyugat of the entered dose are excreted. Most intensively Meksiprim® and it глюкуроноконъюгат is excreted within the first 4 hours after administration of drug. Excretion indicators with Meksiprima® urine and its conjugated metabolite have considerable individual variability.

Indications to use:

- alarming frustration at neurotic and neurosis-like states;
- neurangiosis;
- easy cognitive disorders of various genesis (at the psychoorganic syndrome and asthenic disturbances caused by acute and chronic disorders of cerebral circulation, cherepnomozgovy ravma, neuroinfections and intoxications, senile and atrophic processes);
- dysmnesias and intellectual insufficiency at elderly people;
- influence of extreme (stressorny) factors;
- an alcoholic abstinence syndrome with dominance of neurosis-like and vegetovascular frustration.

Route of administration and doses:

Мексиприм® appoint inside. The applied therapeutic doses and duration of treatment are defined by sensitivity of patients to drug. Begin treatment with a dose of 0,25-0,5 g; the average daily dose makes 0,25-0,5 g, maximum daily - 0,8 g. The daily dose of drug is distributed on 2-3 receptions during the day. For treatment of patients with alarming frustration, vegetovascular dysfunctions and cognitive disturbances of Meksiprim®primenyayut within 2-6 weeks. When stopping an alcoholic abstinence syndrome of Meksiprim® apply within 5-7 days. Course therapy of Meksiprimom® is finished gradually, reducing a drug dose within 2-3 days.

Features of use:

 During treatment it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

Seldom — nausea, dryness of a mucous membrane of an oral cavity, drowsiness, allergic reactions.

Interaction with other medicines:

Мексиприм® it is compatible to psychotropic drugs; strengthens effect of benzodiazepine anxiolytics, protivoparkinsonichesky means and carbamazepine. Reduces toxic effect of alcohol.

Contraindications:

Liver and/or renal failure, the increased individual sensitivity to drug, children's age, pregnancy, breastfeeding.

Overdose:

Symptoms: a sleep disorder (sleeplessness, in certain cases — drowsiness). Treatment: as a rule, it is not required — symptoms disappear independently within a day. In hard cases at sleeplessness it is recommended to accept nitrazepam of 10 mg, oxazepam of 10 mg or diazepam of 5 mg.

Storage conditions:

List B. In dry, protected from light and the place, unavailable to children, at a temperature not above 30 °C.

Issue conditions:

According to the recipe

Packaging:

Tablets, film coated on 125 mg. On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. On 1, 2, 3, 4 or 6 blister strip packagings together with  the application instruction place in a cardboard pack.